Passa al contenuto
Merck
  • Asoxime (HI-6) impact on dogs after one and tenfold therapeutic doses: assessment of adverse effects, distribution, and oxidative stress.

Asoxime (HI-6) impact on dogs after one and tenfold therapeutic doses: assessment of adverse effects, distribution, and oxidative stress.

Environmental toxicology and pharmacology (2011-07-27)
Miroslav Pohanka, Ladislav Novotny, Jana Zdarova-Karasova, Hana Bandouchova, Filip Zemek, Martina Hrabinova, Jan Misik, Kamil Kuca, Jiri Bajgar, Ondrej Zitka, Natalia Cernei, Rene Kizek, Jiri Pikula
ABSTRACT

Asoxime (HI-6) is a well known oxime reactivator used for counteracting intoxication by nerve agents. It is able to reactivate acetylcholinesterase (AChE) inhibited even by sarin or soman. The present experiment was aimed to determine markers of oxidative stress represented by thiobarbituric acid reactive substances and antioxidants represented by ferric reducing antioxidant power, reduced and oxidized glutathione in a Beagle dog model. Two groups of dogs were intramuscularly exposed to single (11.4 mg/kg.b.wt.) or tenfold (114 mg/kg.b.wt.) human therapeutically doses of HI-6. HI-6 affinity for AChE in vitro was evaluated in a separate experiment. Complete serum biochemistry and pharmacokinetics were also performed with significant alteration in blood urea nitrogen, creatine phosphokinase, glucose and triglycerides. Blood samples were collected before HI-6 application and after 30, 60, and 120 min. The overall HI-6 impact on organism is discussed.

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
HI-6, ≥98% (HPLC)